Download presentation
Presentation is loading. Please wait.
1
Supplementary data Figure S1 PBMC 20ug PBMC 5ug PBMC 1.25ug PBMC 0.3ug
CatG Mars116 25kDa CatG
2
Supplementary data Figure S2 Day 1 5 12 14 21 + - BLC PBMC Medium+CSA
Figure S2 Detection of cysteine protease activity during B cell transformation. The active site label DCG-04 was used to visualize active cysteine proteases. Detection of CatD or EBNA was analyzed with anti-CatD or anti-EBNA. Two different experiments n=2 different donors. Figure S2 Day 1 5 12 14 21 + - BLC PBMC Medium+CSA EBV 37kDa CatX CatB DCG-04 25kDa CatS CatD 37kDa CatD Anti-CatD 25kDa -actin 37kDa EBV lysate 75kDa EBNA Anti-EBNA 50kDa
3
Supplementary data Figure S3 Day 1 5 12 14 21 + - BLC AEP Medium+CSA
1 5 12 14 21 + - BLC AEP Medium+CSA EBV 50kDa inactive AEP Anti-AEP 37kDa active 37kDa -chain MHC class II -chain 25kDa -actin 37kDa Figure S3: Levels of AEP during B cell transformation. AEP-specific immunoblot was performed with AEP antibody. Two different experiments n=2 different donors.
4
*** ** Supplementary data Figure S4 mDC1 B cells B cell B cell+EBV
mDC1+EBV FIGURE S4: Short-term EBV exposure to primary B cells and mDC1. B cells or mDC1 were co-cultured with T cells and TTCF with or without EBV for five days. Cytokine secretion was analyzed by ELISA and was carried out in quadruplicate. One representative bar diagram out of n=3 donors is shown (left panel). Cell surface expression of MHC II. EBV-exposed (24 h) B cells or mDC1 were stained with anti-human HLA-DR antibody to detect MHC II expression by flow cytometry (right panel). One representative diagram out of n=2 donors is shown.
Similar presentations
